文献速递支持与姑息治疗

接受免疫检查点抑制剂治疗的癌症患者性别特异性体成分模式与生存及免疫毒性的关联:系统综述与荟萃分析

Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy - A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2023-02-18

该系统综述与荟萃分析检索PubMed、Embase和CENTRAL截至2022年7月的文献,纳入48项超重/肥胖研究(19767例)和32项肌肉减少症研究(3193例)。超重/肥胖与更好的无进展生存(P=0.009)和总生存(P<0.00001)显著相关,男性获益最强,但两性超重/肥胖者发生≥3级免疫相关不良事件风险更高(P=0.0009);肌肉减少症患者无进展生存(P<0.0001)和总生存(P<0.0001)显著缩短,免疫相关不良事件频率无差异。

要点

  • 超重/肥胖与接受ICI治疗癌症患者更好的PFS(P=0.009)和OS(P<0.00001)显著相关。
  • 超重/肥胖男性生存获益最强(PFS P=0.05;OS P=0.0005),女性无获益。
  • 超重/肥胖两性患者≥3级irAEs风险更高(P=0.0009)。

核心结论

  • 该荟萃分析提示,体成分与接受ICI治疗的癌症患者的生存和irAEs以性别特异性方式相关。

研究设计与样本

  • 系统检索PubMed、Embase和CENTRAL截至2022年7月发表的记录,检索词为体成分相关词与ICI方案相关词的组合。
  • 由两名作者独立筛选,纳入报告体重指数或肌肉减少症指标的所有研究。
  • 纳入48项报告超重/肥胖的研究共19767例患者,以及32项报告肌肉减少症的研究共3193例患者。

主要发现

  • 在整个队列中,超重/肥胖与更好的PFS(P=0.009)和OS(P<0.00001)显著相关。
  • 按性别分层分析显示,超重/肥胖男性生存获益最强(PFS P=0.05;OS P=0.0005),超重/肥胖女性患者未显示任何生存获益。
  • 超重/肥胖两性患者发生≥3级irAEs的风险更高(P=0.0009)。
  • 肌肉减少症患者PFS(P<0.0001)和OS(P<0.0001)显著缩短。
  • 肌肉减少症与非肌肉减少症患者之间irAEs频率无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Imbalanced body composition is mechanistically connected to dysregulated immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment results in cancer patients undergoing immune checkpoint inhibitor (ICI) therapy is currently under debate. We aimed to answer if survival rates and occurrence of immune-related adverse events (irAEs) were different in obese or sarcopenic patients. METHODS: A systematic search was conducted in PubMed, Embase and CENTRAL for all records published until July 2022 using specific search terms for body composition in combination with terms for ICI regimens. Two authors screened independently. All studies that reported on body mass index or sarcopenia measures were selected for further analysis. RESULTS: 48 studies reporting on overweight/obesity comprising of 19,767 patients, and 32 studies reporting on sarcopenia comprising of 3193 patients fulfilled the inclusion criteria. In the entire cohort, overweight/obesity was significantly associated with better progression-free survival (PFS; p = 0.009) and overall survival (OS; p <0.00001). Subgroup analyses stratified by sex revealed that overweight/obese males had the strongest survival benefit (PFS: p = 0.05; OS: p = 0.0005), and overweight/obese female patients did not show any. However, overweight/obese patients of both sexes had a higher risk to develop irAEs grade ≥3 (p = 0.0009). Sarcopenic patients showed significantly shorter PFS (p <0.0001) and OS (p <0.0001). The frequency of irAEs did not differ between sarcopenic and non-sarcopenic patients. CONCLUSION: This meta-analysis suggests that body composition is associated in a sex-specific manner with survival and irAEs in cancer patients undergoing ICI treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Trinkner P, Günther S, Monsef I, et al. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy - A systematic review and meta-analysis. Eur J Cancer. 2023. PMID: 36931074. doi:10.1016/j.ejca.2023.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。